B
Bull
Bull · 25%SPRC
$7.05
Scenario price
$1.090
-0.100 (-9.17%)At close
Loading chart…
- High
- 1.210
- Open
- 1.210
- VWAP
- 1.12
- Volume
- 6.00M
- Mkt Cap
- 2.77M
- Low
- 1.070
- Amount
- 6.74M
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
AI analysis of Scisparc Ltd (SPRC)
SellSciSparc Ltd. is not a good buy right now due to its significant recent losses and negative financial indicators. The stock has dropped 91.35% year-to-date and has a current price of $1.09, which is far below its historical performance. Additionally, the RSI is extremely low at 5.451, indicating that the stock is oversold and may continue to decline. The company also reported a net margin of -2041.65% in Q2 2025, highlighting severe profitability issues. The main risk is the ongoing decline in stock price, with a 5-day change of -35.88%.
Valuation Metrics
The current forward P/E ratio for Scisparc Ltd (SPRC) is 0.00, compared to its 5-year average forward P/E of -7.26.
Alphio AI Price Scenarios for SPRC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.010-22NewsfilterSciSparc's Subsidiary Advances Tourette Syndrome Clinical Trial
- 4.510-19Newsfilter
SciSparc Shifts Strategic Focus to Agentic AI Technologies
- 4.510-15Newsfilter
SciSparc Shifts Strategic Focus to Agentic AI Technologies
- 8.509-02Newsfilter
NeuroThera Pursues FDA Orphan Drug Designation for SCI-110
- 4.508-26Newsfilter
SciSparc Appoints AI Expert to Strengthen Strategic Focus
SPRC FAQ — answered by Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
SciSparc Ltd. is not a good buy right now due to its significant recent losses and negative financial indicators. The stock has dropped 91.35% year-to-date and has a current price of $1.09, which is far below its historical performance. Additionally, the RSI is extremely low at 5.451, indicating that the stock is oversold and may continue to decline. The company also reported a net margin of -2041.65% in Q2 2025, highlighting severe profitability issues. The main risk is the ongoing decline in stock price, with a 5-day change of -35.88%.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.